This non-serious spontaneous report from the United States received on 11-NOV-2015 by a physician, via a sales 
representative, describes the occurrence of Aggression, Anger and Condition aggravated in a 9 year-old Caucasian
female patient taking Vyvanse (LISDEXAMFETAMINE DIMESYLATE) for Attention deficit/hyperactivity disorder 
(ADHD).
No past medical history for the patient was reported. The concurrent medical history for the patient included: Anger,
Abnormal behavior, Insomnia. No allergy history for the patient was reported. No procedure history for the patient 
was reported. 
Concomitant medications included: CLONIDINE HYDROCHLORIDE, Bromfed DM (BROMPHENIRAMINE 
Print Time: 15-JUL-2016 02:45 PM If a field is blank, there is no data for that field Page 83 of 250
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, PSEUDOEPHEDRINE HYDROCHLORIDE).
The patient commenced treatment with Vyvanse on 06-MAY-2014. On 06-MAY-2014 the dose was 60 mg, 
1x/day:qd.
The patient developed the following adverse events: Aggression; Anger described as increased anger outbursts 
characterizing the event of condition aggravated which started on 04-NOV-2014. Treatment, if any, was unknown. 
Due to the event, therapy with Vyvanse was discontinued on 04-NOV-2014 and the patient was switched to 
methylphenidate. The outcome of the events was resolved on 26-NOV-2014. 
The following events were considered non-serious: Aggression, Condition aggravated, Anger.
The causality was assessed by a physician for the events of Aggression, Anger, Condition aggravated as Definite to
Vyvanse.
Follow up information was received by the physician on 05-JAN-2016. Patient information, medical history, 
concomitant medications, added events of Anger and Condition aggravated, event start and stop dates, causality 
and the narrative were updated to reflect the additional information provided.